• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC

New Search Back to Search Results
Note: this medical device has supplements. The device description may have changed. Be sure to look at the supplements to get an up-to-date view of this device.
Classification Nameassay,hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
Generic Nameassay,hybridization and/or nucleic acid amplification for detection of hepatitis c rna,hepatitis c virus
725 potter street
berkeley, CA 94710
PMA NumberP020022
Date Received06/19/2002
Decision Date03/28/2003
Withdrawal Date 02/26/2015
Product Code
MZP[ Registered Establishments with MZP ]
Docket Number 04M-0538
Notice Date 12/08/2004
Advisory Committee Microbiology
Expedited Review Granted? Yes
Combination Product No
Approval Order Statement 
Approval for the bayer versant hcv rna 3. 0 assay (bdna). The device is indicated for: the versant hcv rna 3. 0 assay (bdna) is a signal amplification nucleic acid probe assay for the quantitation of human hepatitis c viral rna (hcv rna) in the serum or plasma (edta and acd) of hcv-infected individuals using the bayer system 340 bdna analyzer. Specimens containing hcv genotypes 1-6 have been validated for quantitation in the assay. The versant hcv rna 3. 0 assay is intended for use as an aid in the management of hcv-infected patients undergoing anti-viral therapy. The assay measures hcv rna levels at baseline and during treatment and are useful in predicting non-response to hcv therapy, and are predictive of non-sustained virological response. The results from the versant hcv rna 3. 0 assay (bdna) must be interpreted within the context of all relevant clinical and laboratory findings. Assay performance characteristics have been established only for individuals treated with interferon alfa-2b plus ribavirin. No information is available on the assay predictive values when other therapies are used.
Approval Order Approval Order
Summary Summary of Safety and Effectiveness
Labeling Labeling
Supplements: S001 S002 S003 S004 S005 S006 S007 S008 S009 
S010 S011